Successful Brain Delivery of Andrographolide Loaded in Human Albumin Nanoparticles to TgCRND8 Mice, an Alzheimer&#8217;s Disease Mouse Model by Bilia, Anna Rita et al.
1 August 2019 | Volume 10 | Article 910
ORIGINAL RESEARCH
doi: 10.3389/fphar.2019.00910
published: 22 August 2019
Frontiers in Pharmacology | www.frontiersin.org
Edited by: 
Rosario Pignatello, 
University of Catania, Italy
Reviewed by: 
Luca Ferraro, 
University of Ferrara, Italy 
Wladyslaw Lason, 
 Polish Academy of Sciences, Poland
*Correspondence: 
Anna Rita Bilia 
ar.bilia@unifi.it
Specialty section: 
This article was submitted to 
Neuropharmacology, 
a section of the journal 
Frontiers in Pharmacology
Received: 01 March 2019
Accepted: 18 July 2019
Published: 22 August 2019
Citation: 
Bilia AR, Nardiello P, Piazzini V, 
Leri M, Bergonzi MC, Bucciantini M 
and Casamenti F (2019) Successful 
Brain Delivery of Andrographolide 
Loaded in Human Albumin 
Nanoparticles to TgCRND8 Mice, an 
Alzheimer’s Disease Mouse Model. 
Front. Pharmacol. 10:910. 
doi: 10.3389/fphar.2019.00910
Successful Brain Delivery of 
Andrographolide Loaded in Human 
Albumin Nanoparticles to TgCRND8 
Mice, an Alzheimer’s Disease Mouse 
Model
Anna Rita Bilia 1*, Pamela Nardiello 2, Vieri Piazzini 1, Manuela Leri 2,3, 
Maria Camilla Bergonzi 1, Monica Bucciantini 3 and Fiorella Casamenti 2
1 Dipartimento di Chimica “Ugo Schiff,” University of Florence, Florence, Italy, 2 Dipartimento di Neuroscienze, Psicologia, 
Area del Farmaco e Salute del Bambino (NEUROFARBA), University of Florence, Florence, Italy, 3 Dipartimento di Scienze 
Biomediche, Sperimentali e Cliniche “Mario Serio,” University of Florence, Florence, Italy
Andrographolide (AG) was encapsulated in human albumin nanoparticles (AG NPs), and 
their crossing properties of the blood-brain barrier (BBB), brain distribution, and effects 
in TgCRND8 mice were evaluated. The development of appropriate NP formulations is 
mandatory because of the scarce BBB permeability properties of AG. Developed NPs 
had proper size (mean size: 159.2 ± 4.5 nm), size distribution (PDI nearby 0.12 ± 0.01), 
and ζ potential (-24.8 ± 1.2 mV), which were not affected by sodium fluorescein (NAF) 
loading. When AG was loaded to NPs, it slightly affected their size (210.4 ± 3.2 nm) and ζ 
potential (-20.3 ± 1.5) but not the PDI. Both NAF and AG had a remarkable encapsulation 
efficiency (more than 99%). The in vitro release of AG from the NPs reached the highest 
percentage (48%) after 24 h, and the Higuchi’s equation was found to be the best fitting 
model (R2 = 0.9635). Both AG and AG NPs did not alter the viability of N2a murine 
neuroblastoma cells when compared with the untreated control cells. In the step-down 
inhibitory avoidance test, AG NPs administered to TgCRND8 mice significantly improved 
their performance (P < 0.0001), reaching levels comparable to those displayed by wild-
type mice. In the object recognition test, treated and untreated animals showed no 
deficiencies in exploratory activity, directional movement toward objects, and locomotor 
activity. No cognitive impairments (discrimination score) were detected in TgCRND8 mice 
(P < 0.0001) treated with AG NPs. After acute intravenous administration (200 µl), NPs 
loaded with the probe NAF were detected in the brain parenchyma of TgCRND8 mice. 
Immunofluorescent analyses evidenced the presence of NPs both in the pE3-Aβ plaque 
surroundings and inside the pE3-Aβ plaque, indicative of the ability of these NPs to cross 
the BBB and to penetrate in both undamaged and damaged brain tissues. Furthermore, 
the immunohistochemical analysis of GFAP-positive astrocytes in the hippocampus of Tg 
mice evidenced the anti-inflammatory activity of AG when AG NPs were intraperitoneally 
administered. AG was not effective in counteracting amyloid Aβ aggregation and the 
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INTRODUCTION
Dementia, an umbrella term to describe symptoms of impairment 
in memory, communication, and thinking, has been declared by 
the World Health Organization (WHO) as a priority condition 
through the Mental Health Gap Action Programme. The cost 
of dementia according to the WHO, treating and caring for 
people with dementia, currently costs the world more than US$ 
604 billion per year, but prevalence and incidence projections 
indicate that the number of people with dementia will continue 
to grow. An estimate of the future cost of dementia in Europe is a 
rise of 43% from 2008, reaching 250 billion Euros in 2030 (World 
Health Organization, 2012). The WHO’s report has been recently 
confirmed by the Alzheimer’s Disease International (ADI) 
research, which has estimated nearly double number of patients 
every 20 years, up to 65.7 million in 2030 and up to 115.4 million 
in 2050. Much of the increase will be in developing countries, the 
fastest growth in the elderly population is taking place in China, 
India, and their south Asian and western Pacific neighbors. 
The most common cause of dementia among elderly adults 
is Alzheimer’s disease (AD), currently affecting in developed 
countries approximately 30 million aged people and is expected 
to increase dramatically by 2050—when people aged 60 and over 
will account for 22% of the world’s population with four-fifths 
living in Asia, Latin America, or Africa (Prince et al., 2015).
Main clinical symptoms of AD include memory impairment 
and global cognitive deficits that can lead to dementia with the 
disease progression and noncognitive symptoms, especially 
loss of motor functions, such as gait disturbances, disturbed 
activity level and balance. Although the exact etiology of AD 
is not fully understood, substantial evidence indicates that 
amyloid-β peptide (Aβ), derived from sequential cleavage of 
amyloid protein precursor (APP) by β- and γ-secretases, plays 
a central role in the pathogenesis of AD (Hardy and Higgins, 
1992). To date, there is no effective treatment for AD, and 
current therapeutic strategies only alleviate or treat disease 
symptoms but do not treat the underlying disease or delay 
its progression. Accordingly, researchers are looking for new 
multitarget drugs and combinatorial therapies to treat AD, 
including anti-inflammatory, antioxidant, and anti-amyloid 
approaches. Hence, studies are carried out using several cell 
lines associated with inherited APP mutations, neurotoxicity 
of soluble oligomeric Aβ when applied to neurons, and APP-
overexpressing mice that recapitulate certain neuropathologic 
and behavioral features of AD.
In this study, a natural product, andrographolide (AG, 
Figure  1), the main labdane diterpenoid from the Asian 
medicinal plant Andrographis paniculata, was investigated for 
its potential role in the treatment of AD patients. AG use looks 
promising for the broad range of multifunctional properties, 
principally antioxidant, neuroprotective, and anti-inflammatory 
(Asprea et al., 2019). Hence, inhibition of lipopolysaccharide-
induced overexpression of HMGB1, TLR4, NFκB, COX-2, and 
iNOS and release of inflammatory mediators in primary mix glial 
culture adult mice prefrontal cortex and hippocampus region are 
reported for AG. Active microglial and reactive astrocytic markers 
can be also downregulated after AG treatment. In addition, AG 
decreases the expression of proapoptotic genes and enhances that 
of antiapoptotic genes, reducing neurodegeneration (Das et al., 
2017; Kishore et al. 2017). AG has a neuroprotective role in a 
rat model of permanent cerebral ischemia (Chan et al., 2010) 
and prevents neuropathological changes in the APPswe/PS1ΔE9 
mouse model, improving the spatial memory (Serrano et al., 
2014). AG also induces the proliferation and the generation of 
new neurons in the adult hippocampus of wild-type (wt) and 
APPswe/PS1ΔE9 mice (Varela-Nallar et al., 2015).
Besides these recent studies highlighting the numerous 
different molecular targets of AG and their possible implications 
for Alzheimer’s disease treatment, AG has a low bioavailability 
that can greatly limits its biodistribution and localization and a 
resulting toxicity but significantly decreased the oxidative stress levels. In conclusion, AG 
NPs have extraordinary versatility, nontoxicity, nonimmunogenicity, strong biocompatibility, 
high biodegradability, and astonishing loading capacity of drug.
Keywords: andrographolide, blood-brain barrier, human albumin nanoparticles, TgCRND8 mice, step-down 
inhibitory avoidance test, object recognition test, amyloid
FIGURE 1 | Structure of andrographolide (AG).
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very short biological half-life (t½ = 2 h) (Asprea et al., 2019). 
Recently, we have reported AG scarce permeability across the 
human monoculture in vitro blood-brain barrier (BBB) model 
based on human immortalized hCMEC/D3 cell line (Guccione 
et al., 2017). The experimental data confirmed that free AG did 
not affect cell layer integrity but did not significantly permeate 
the human immortalized hCMEC/D3 cell line (Guccione et al., 
2017). This behavior was also confirmed by in silico predictions 
mainly because of the presence of five oxygen atoms in AG 
structure (ideally the number of oxygen atoms should not 
exceed three for ‘‘BBB + drugs”), with a rather high molecular 
polar surface area (above the threshold value of 70 Å, which 
clearly disfavors BBB permeation). The above data suggested 
that AG could represent a proper candidate to develop smart 
delivery systems for targeting the brain (Bilia et al., 2017, Bilia 
et al., 2018). We focused on nanoscale systems, human albumin 
polymeric nanoparticles (NPs), as a potential successful strategy 
able to increase stability and biopharmaceutical characteristics 
of AG, enhancing its penetration across the BBB because of 
their adsorptive transcytosis, targeting specific brain sites, and 
increasing therapeutic efficacy.
Accordingly, NPs loaded with AG (AG NPs) were administered 
to TgCRND8 mice, which express a transgene incorporating 
both the Indiana mutation (V717F) and the Swedish mutation 
(K670N/M671L) in the human amyloid-β protein precursor 
(APP) gene. The TgCRND8 mouse is a well-known model 
for reproducing important features of AD, including amyloid 
plaques and cognitive deficits (Bellucci et al., 2006). Interestingly, 
these mice display profound cognitive deficits at 2–3 months of 
age when few AD Aβ neuropathologies can be observed (Chishti 
et al., 2001).
Furthermore, to better understand the biological effects of 
AG, the potential ability of AG to modulate Aβ aggregation 
and to destabilize amyloid fibrils blocking the neurotoxicity of 
Aβ peptide, inhibiting a key step in the pathogenesis of AD, was 
investigated. Indeed, because of the recognized importance of 
misfolded aggregates in amyloid diseases, in recent years, the 
antiaggregation and protective effects of many different natural 
substances have been investigated, although with very variable 
results. Hence, numerous compounds have been shown to be 
active in the test tube, but their effectiveness in vivo, particularly 
in the real disease in humans, results were limited because of 
their poor stability and bioavailability.
MATERIALS AND METHODS
Chemicals and Reagents
Human serum albumin, AG (purity 98%), NAF, sodium chloride 
(NaCl), sodium hydroxide (NaOH), phosphate buffered saline 
(PBS) bioperformance certified, dimethyl sulfoxide (DMSO), 
acetonitrile HPLC grade, methanol HPLC grade, formic acid 
analytical grade, hydrochloric acid (HCl) analytical grade, and 
ethanol analytical grade were purchased from Sigma-Aldrich 
(Milan, Italy). Water was purified by a Milli-Q Plus system from 
Millipore (Milford, CT, USA). Phosphotungstic acid (PTA) 
was from Electron Microscopy Sciences (Hatfield, PA, USA). 
Dialysis kit was from Spectrum Laboratories, Inc. (Breda, The 
Netherlands). RHB (150 mM NaCl, 2.2 mM CaCl2, 0.2 mM 
MgCl2, 5.2 mM KCl, 2.8 mM glucose, 5 mM HEPES, 6 mM 
NaHCO3) was prepared in-house, adjusted to pH 7.4, filtered, 
and stored at 4°C.
Production and Characterization of NPs
Preparation of NAF NPs
Fluorescent human albumin NPs (NAF NPs) were prepared by 
thermal cross-linking (Bergonzi et al., 2016). Briefly, ethanol 
(4 ml) was added at a rate of 1 ml/min to 10 mM NaCl solution 
(4 ml) of human albumin (0.5% w/v) and NAF (0.5% w/v) under 
magnetic stirring (500 rpm) at room temperature. Stirring was 
continued at 90°C for 1 h to induce the thermal cross-linking 
of albumin. The obtained fluorescent NPs were purified by three 
cycles of centrifugation (1,358 g, 30 min) and dispersed in NaCl 
10 mM. The concentration was set to 1 mg NAF/mL suspension. 
The suspension was used as such after quantification of NAF.
Preparation of AG NPs
AG NPs were obtained by thermal cross-linking, optimizing the 
method recently reported in our previous work (Guccione et al., 
2017). In brief, 20 mg of AG were solubilized in 4 ml of ethanol, 
while human albumin (0.5% w/v) was dissolved in 4 ml of 10 mM 
NaCl. The AG solution was added at a rate of 1 ml/min to human 
albumin solution under magnetic stirring (500 rpm). Stirring was 
prolonged for 1 h at 90°C to obtain NPs. The resulting suspension 
was purified by centrifugation (1,358 g, 30 min × three times). The 
centrifuged particles were dispersed in NaCl 10 mM to obtain a 
final concentration of 1 mg AG/ml of suspension. The suspension 
was used as such after quantification of AG.
Yield of NPs
The yields of each NP preparation process were determined as 
the weight percentage of the final product after drying compared 
with the total amount of materials used for the formulation.
HPLC-DAD and HPLC-FLD Methods
The quantification of AG was performed on an HP 1200 liquid 
chromatograph equipped with a DAD detector. The column 
was a 150 mm × 4.6 mm i.d., 5 µm Kinetex EVO, RP18. The 
mobile phases were (A) CH3CN and (B) formic acid/water pH 
3.2. Flow rate was 0.8 ml/min, and temperature was set to 27°C. 
The following gradient profile was utilized: 0–2 min, 5–15% A, 
95–85% B; 2–5 min, 15% A, 85% B; 5–7 min 15–50% A, 85–50% 
B; 7–12 min, 50% A, 50% B; 12–15 min, 50–30% A, 50–70% B; 
15–20 min, 30% A, 70% B; 20–25 min, 30–5% A, 70–95% B with 
equilibration time of 5 min. The UV/vis spectra were recorded 
in the range 200–800 nm, and the chromatograms were acquired 
at 223 nm.
NAF (λex = 460 nm, λem = 515 nm, green) analyses were 
performed using an HPLC 1200 liquid chromatograph equipped 
with an FLD detector, with the column used for AG maintained 
at 27°C.
The mobile phases were (A) CH3CN and (B) formic acid/
water pH 3.2. Flow rate was 0.8 ml/min. The following gradient 
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profile was utilized: 0–3 min, 20% A, 80% B; 3–23 min, 20–80% 
A, 80–20% B; 23–25 min 80–100% A, 20–0% B; 25–27 min, 100–
20% A, 0–80% B with equilibration time of 5 min.
The linearity range of responses of AG and NAF dissolved 
in CH3OH and water, respectively, was determined on five 
concentration levels using three injections for each level (AG 
from 0.05 to 20 µg/ml, NaF from 0.05 to 35 µg/ml). Both curves 
showed a coefficient of linear concentration above than 0.999. 
limit of quantitation (LOQ) and limit of detection (LOD) of AG 
resulted in 5.3 ng and 2.6 ng, respectively.
Encapsulation Efficiency and Loading Capacity
The amount of AG entrapped into NPs was calculated using an 
indirect method, previously described in our studies (Bergonzi 
et al., 2016; Grossi et al., 2016).
NPs were purified by ultracentrifugation for 75 min at 
18,000  rpm and 4°C. Encapsulation efficiency (EE%) and the 
loading capacity (LC%) were calculated as follows:
EE% = (Total Drug-Free Drug)/(Total Drug) · 100
LC% = (Total Drug-Free Drug)/(Weight of NPs) · 100
AG quantifications were carried out on a reverse-phase HPLC 
system, as described in the previous session.
NPs Morphology, Shape, Size, and ζ Potential
NPs were characterized by transmission electron microscopy 
(TEM), dynamic light scattering (DLS), and electrophoretic light 
scattering (ELS). All dispersions of NPs were diluted 10 times 
before to be applied to a carbon film-covered copper grid. PTA 
solution (1% w/v) was used as contrast color. The samples were 
dried and then examined under a TEM JEOL 1010 electron 
microscope and photographed at an accelerating voltage of 64 kV.
DLS and ELS analyses were performed with a Zetasizer Nano 
series ZS90 (Malvern Instruments, Malvern, UK) equipped with 
a JDS Uniphase 22mW He-Ne laser operating at 632.8 nm, an 
optical fiber-based detector, a digital LV/LSE-5003 correlator, 
and a temperature controller (Julabo water bath) set at 25°C.
The hydrodynamic diameter of the particles (Zh) and the particle 
size distribution (polydispersity index, PDI) were analyzed using 
the ALV-60X0 software V.3.X provided by Malvern. The ζ potential, 
indicating the electric charge on the NPs surface and the physical 
stability of the formulations, was calculated by the Helmholtz-
Smoluchowsky equation using the same instrument.
Storage Stability
Stability of AG NPs was investigated by monitoring their physical 
characteristics, namely hydrodynamic diameter, PDI, ζ potential, 
and EE% over 30 days at 4°C.
In Vitro Release Studies
In vitro release of AG was investigated employing the permeable 
membrane bag method using regenerated cellulose membranes 
with a molecular cutoff of 3.5 kD. Phosphate buffer solution 
(PBS, pH 7.4) was selected as release medium. Two milliliters of 
AGNPs was added into the membrane bag and placed in 200 ml of 
release medium. The system was incubated at 37°C with stirring 
at 150 rpm. At predetermined time intervals (0, 0.5, 1, 2, 3, 4, 6, 
9, 24 h), 1 ml of the medium was withdrawn and replaced with 
the same volume of fresh release medium maintained at 37°C to 
preserve sink conditions. Released AG at each time interval was 
quantified using HPLC-DAD. The experiments were performed 
in triplicate.
AG release data were fitted using Korsmeyer-Peppas, Hixson 
Crowell, Higuchi, first-order and zero-order mathematical 
models to understand the release pattern of entrapped compound 
from developed NPs. The regression analysis was performed to 
obtain the best fit correlation.
In addition, NAF release was studied using the same method 
to evaluate the stability of fluorescent NAF NPs. The test time 
was set up to 3 h, according to the in vivo tests. At predetermined 
time intervals (0, 0.5, 1, 2, 3 h), 1 ml of the medium was 




Aβ1-42 aggregates grown for different times (0, 3, 24, 48, and 
72 h) in the absence or in the presence of AG were diluted 
with 20 mM phosphate buffer, pH 7.4, at 25°C to a 15-μM 
peptide concentration and supplemented with a small volume 
of a 1.0-mM Thioflavin T (ThT) solution to a 20 μM final ThT 
concentration. Then, each sample was transferred into multiple 
wells of a 96-well half-area, low-binding, clear bottom (200 μl/
well), and ThT fluorescence was read at the maximum intensity 
of fluorescence of 485 nm using a Biotek Synergy 1H plate reader; 
the ThT fluorescence of buffer was subtracted from all samples’ 
fluorescence values. To ascertain any AG interference on ThT 
fluorescence, we performed control experiments where AG was 
added in pre-made Aβ42 aggregates either immediately before or 
after the addition of ThT solution.
TEM Imaging
Five-microliter aliquots of aggregating Aβ42 in the presence or 
in the absence of AG were withdrawn at different aggregation 
times, loaded onto formvar/carbon-coated 400 mesh nickel grids 
(Agar Scientific, Stansted, UK) and negatively stained with 2.0% 
(w/v) uranyl acetate (Sigma-Aldrich). The grid was air-dried and 
examined using a JEM 1010 transmission electron microscope 
(TEM) at 80 kV excitation voltage.
MTT Assay
N2a murine neuroblastoma cells (ECACC) were seeded 
into 96-well plates at a density of 5,000 cells/well in MEM 
supplemented with non-essential amino acids, 10% FCS, 
antibiotics, and glutamine, cultured for 24 h. To access the cell 
viability after AG and AG NP exposure, an MTT assay was 
performed. The cells were treated with different concentrations 
of either AG or AG NPs (1, 2, and 3 µM) for increasing time 
periods (4, 24, and 48 h) and evaluated for viability by the MTT 
assay, as previously described (Grossi et al., 2013). After 24 h 
of incubation, the culture medium was removed, and the cells 
were incubated for 1.0 h at 37°C in 100 μl of serum-free DMEM 
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without phenol red, containing 0.5 mg/ml MTT. Then, 100 μl 
of cell lysis solution (20% SDS, 50% N,N-dimethylformamide) 
was added to each well, and the samples were incubated at 
37°C for 2 h to allow complete cell lysis. The absorbance of 
the blue formazan resulting from MTT reduction was read at 
570 nm using a spectrophotometric microplate reader. The final 
absorption values were calculated by averaging each sample in 
triplicate and subtracting the blank (100 μl of MTT solution + 
100 μl of lysis solution) value.
Immunofluorescence
Subconfluent N2a cells grown on glass coverslips were treated 
for 24 h with Aβ42 samples (2.5 μM) grown in the presence or 
in the absence of AG and then washed with PBS. GM1 labeling 
was performed by incubating the cells with 10 ng/ml CTX-B 
Alexa 488 in complete medium for 10 min at room temperature. 
Then the cells were fixed in 2.0% buffered paraformaldehyde 
for 10 min and permeabilized by treatment with a 1:1 acetone/
ethanol solution for 4.0 min at room temperature, washed with 
PBS, and blocked with PBS containing 0.5% BSA and 0.2% 
gelatin. After incubation for 1.0 h at room temperature with 
rabbit anti-Aβ42 polyclonal antibody diluted 1:600 in blocking 
solution, the cells were washed with PBS for 30 min under 
stirring and then incubated with Alexa 568-conjugated anti-
rabbit secondary antibody (Molecular Probes) diluted 1:100 in 
PBS. Finally, the cells were washed twice in PBS and once in 
distilled water to remove non-specifically bound antibodies. 
Cell fluorescence was imaged using a confocal Leica TCS SP5 
scanning microscope (Leica, Mannheim, Ge) equipped with 
a HeNe/Ar laser source for  fluorescence measurements. The 
observations were performed using a Leica Plan 7 Apo X63 oil 
immersion objective (Nosi et al., 2012).
In Vivo Studies
Ethics Statement
Transgenic (Tg) CRND8 mice harboring a double-mutant gene 
of APP695 (Chishti et al., 2001) and wt control littermates were 
used in accordance with the principles of the Basel Declaration 
and the Working document on genetically altered animals—
CORRIGENDUM of 24 January 2013—of the National Competent 
Authorities for the implementation of Directive 2010/63/EU on 
the protection of animals used for scientific purposes. According 
to the Italian Regulation (D.Lvo 26/2014), the protocol was revised 
and approved by the Animal Welfare Body of the University of 
Florence and licensed by the Italian Competent Authority (Italian 
Ministry of Health, license number 152/2014-B).
Animals
Four-month-old Tg and wt mice (n = 6/group/genotype, 
equally divided for sex) were used. Animals were housed in 
macrolon cages with food and water ad libitum and maintained 
on a 12-h light/dark cycle at 23°C. All efforts were made to 
minimize the number of animals used and their suffering.
Systemic Administration of NAF NPs and AG NPs
Intravenous Injection of NAF NPs
First, we checked for the ability of NPs to cross the BBB in 
TgCRND8 mice acutely dosed with NAF NPs (200 µl, 1 mg/ml 
solution) or vehicle (0.9% NaCl) by intravenous (i.v.) injection 
by the tail vein. Three hours after the administration, mice were 
perfused transcardially with saline solution (0.9%) to remove 
blood components and then with 4% ice-cold paraformaldehyde 
in 0.1M PBS, pH 7.2, under deep anesthesia [Zoletil 80/mg/kg, 
intraperitoneally (i.p).].
Intraperitoneal Administration of AG
Second, Tg and wt mice were administered i.p. with AG NPs 
dissolved in saline (4 mg/kg) for 4 weeks (three times a week). The 
animals were weighted once a day, the body weight was recorded, 
and the dose to be administered i.p. was recalculated according to 
the body weight. After completing the behavioral tests, Tg mice 
were perfused transcardially with saline solution (0.9%) to remove 
blood components and then with 4% ice-cold paraformaldehyde in 
0.1 M PBS, pH 7.2, under deep anesthesia (Zoletil 80/mg/kg, i.p).
Behavioral Experiments
After AG NP administration, treated and untreated Tg and wt 
mice were behaviorally tested.
Step-Down Inhibitory Avoidance Test
The apparatus and procedures used for the step-down inhibitory 
avoidance test were previously described (Grossi et al., 2013). On 
day 1 (training test, TT), each mouse was placed on the platform 
and received an electric shock for 3 s when it stepped down placing 
all paws on the grid floor. Responsiveness to the punishment in 
the TT was assessed by animal vocalization; only those mice that 
vocalized touching the grid (about 70% of mice) were used for 
retention test (RT). Twenty-four hours after TT, each mouse was 
placed on the platform again (RT). The latencies were measured, 
considering 180 s as the upper cutoff, during TT and RT. The 
tests were carried out between 10:00 A.M. and 1:00 P.M.
Object Recognition Test
The apparatus and procedures used for object recognition test 
(ORT) were previously described (Grossi et al., 2013). Briefly, a 
session of two trials (T1 and T2) at 60-min interval was given 
on the test day. In T1, the time spent by each mouse exploring 
two identical 8.0 cm side gray cubes presented for 10 min in two 
opposite corners of the box was recorded. During T2, an 8.0 cm 
side gray cylinder replaced one of the cubes, and the mice were 
left in the box for 5 min. The times spent for the exploration of 
the familiar (F) and the new (N) object were recorded, and a 
discrimination score (D = N/N + F) was calculated.
Animal Tissue Processing
After completing the behavioral tests, the mice were transcardially 
perfused as reported above, brains were quickly extracted and 
fixed in phosphate-buffered (PBS) 4% paraformaldehyde (pH 
7.4) for 24 h at 4°C. Subsequently, brains were rinsed with PBS 
for 24 h, dehydrated using an automated machine, and paraffin 
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embedded. Coronal sections (5.0 µm) were cut using a microtome 
and mounted on slices.
Histochemistry and Fluorescent 
Immunohistochemistry
Histochemical and fluorescent immunohistochemical analyses 
were performed on 5.0-µm coronal paraffin-embedded sections, 
as previously described (Luccarini et al., 2015). Pyroglutamate3 
(pE3)-amyloid-β (pE3-Aβ)-positive plaques were detected by 
the N3pE antibody (dilution 1:200; IBL International, Hamburg, 
Germany), and astrocytes were visualized by the GFAP antibody 
(1:500 dilution; Millipore, Billenca, MA, USA). The sections 
were coverslipped using ProLong (Lyfe Technologies, NY, USA) 
mounting medium with DAPI for nuclear staining. Representative 
images were acquired by an Olympus BX63 microscope coupled 
to CellSens Dimension Imaging Software version 1.6 (Olympus, 
Milan, Italy).
Statistical Analysis
Two- and one-way ANOVA, plus Bonferroni’s post hoc test, 
were used to analyze step-down inhibitory avoidance and ORT 
data, respectively, and Student’s t test for MTT and ROS assays. 
Calculations were performed using either Excel or GraphPad 
Prism version 5.0 for Windows, with statistical significance 
established at P < 0.05. Data are reported as mean values ± 
standard error of the mean (SEM).
RESULTS
Preparation and Characterization of NPs
NPs were produced using a thermal cross-linking method at 
physiological pH, without the requirement of solvents or glass 
beads. Briefly, NPs were obtained by heating at 90°C for 1 h 
human serum albumin. AG NPs and NAF NPs were prepared 
by adding AG or NAF before the heating process. Stability of 
both NAF and AG was good during this process, giving very 
high yields of loading. The developed method of synthesis was 
simple, environment friendly, and with a high reproducibility 
in terms of yield and NPs size (n = 20). The yields of preparative 
process were ca. 80% for NAF NPs and ca. 87% for AG NPs. 
The resulting NPs were roughly spherical, with a reasonably 
regular structure, as evidenced by TEM analysis, which 
provided details on morphology (Figure 2). DLS analysis was 
consistent with TEM analysis in terms of size, confirming a 
monodispersed size distribution and, in addition, showed a 
negatively charged ζ potential for all NPs, even after AG or 
NAF loading. All the DLS data are reported in Table 1. AG and 
NAF loading and EE% were obtained by HPLC analysis using 
the analytical method described in the experimental part. 
Data are given in Table 1. It is remarkable that the mean size of 
unloaded NPs was ca. 150 nm, and it was only slightly affected 
by the NAF loading (mean size: 159.2 ± 4.5 nm). NAF NPs had 
a proper narrow size distribution (PDI nearby 0.12 ± 0.01), and 
physical stability was supposed by the high negative charge. 
AG NPs slightly affected the size of NPs (210.4 ± 3.2 nm) but 
not the PDI (0.10 ± 0.01), which was highly monodispersed. 
High physical stability was expected because of the suitable ζ 
potential values.
Physical and Chemical Stability of AG NPs
Stability of the developed AG NPs was investigated in terms of 
dimensions, PDI, ζ potential, residual drug loading (%) over 
30 days at 4°C using the NP suspension. From the above 
data, storage  did not affect any investigated parameters as 
reported in Table 2.
FIGURE 2 | TEM analysis of AG NPs.
TABLE 1 | Characterization of developed HA NPs in terms of mean diameter, 
polydispersity, ζ potential, yield of preparative process, encapsulation efficiency, 
and loading capacity (mean ± SD; n = 3).
Nanoparticles Size (nm) PDI ζ Potential 
(mV)
EE%
NAF NPs 159.2 ± 4.5 0.12 ± 0.01 -24.8 ± 1.2 99.5 ± 0.1
AG NPs 210.4 ± 3.2 0.10 ± 0.01 -20.3 ± 1.5 99.1 ± 0.2
TABLE 2 | Stability of developed AG NPs in terms of mean diameter, 










Size (nm) 210.8 ± 1.2 211.4 ± 2.5 212.6 ± 0.8 212.9 ± 2.3
PDI 0.10 ± 0.01 0.12 ± 0.02 0.09 ± 0.01 0.10 ± 0.01
ζ potential (mV) -20.5 ± 4.4 -20.1 ± 2.7 -21.3 ± 4.8 -20.2 ± 1.1
Residual drug 
loading (%)
99.1 ± 0.2 98.8 ± 0.4 98.8 ± 0.3 98.7 ± 0.2
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In Vitro Release Studies From AG NPs
Release study was developed to quantify the amount and extent 
of AG release from NPs. The test was carried out during 24 h 
using the membrane bag method in a PBS solution at pH 7.4 
to mimic the sink conditions. Figure 3 depicts the AG released 
during time from AG NPs. The curve was typical for controlled 
release without a burst effect at the beginning of the test, which 
was in agreement with a complete entrapment of AG into NPs. 
The highest percentage of released AG during 24 h test was ca. 
48%. Calculation of the percentage of AG released in the medium 
used the formula previously reported (Guccione et al., 2017). 
Different mathematical equation models were investigated to 
better describe AG process of release from NPs and determine 
the kinetics. The release data were fitted to many kinetic models, 
and the Higuchi kinetic was shown to be the best fitting model, 
as reported in Figure 4.
In Vitro NAF Release Studies From NAF 
NPs
NAF release was studied using the same method for AG to 
evaluate the stability of fluorescent NPs. The test time was set to 
3 h, the same time of the in vivo tests. At predetermined time 
intervals (0, 0.5, 1, 2, 3 h), 1 ml of the medium was withdrawn 
and replaced with fresh PBS. The samples were analyzed using 
HPLC-FLD as reported in the experimental part. No traces of 
NAF were detected during the experimental time, evidencing the 
lack of NAF release from NPs.
Effects of AG on Aβ Amyloid Aggregation
The data presently available in the literature suggest that AG could 
provide a protective and therapeutic effect against a number of 
pathologies, including AD. Such a protection could be caused, 
FIGURE 3 | Release of AG from NPs in PBS, pH 7.4. Data displayed as mean ± SD (n = 3).
FIGURE 4 | Higuchi mathematical equation model best fitted the AG release data from NPs.
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at least in part, by its possible ability to inhibit the amyloid 
aggregation process of Aβ peptide. For this aim, the kinetics of 
fibril formation were monitored by following the increase of ThT 
fluorescence emission intensity at 485 nm during the in  vitro 
Aβ fibrillation process in the absence or in the presence of two 
different concentrations of AG (1X- and 3X-AG). Figure 5A 
shows that the presence of AG in Aβ aggregation solution led 
to a decrease in the apparent ThT fluorescence because of its 
quenching effect (Figure 5A inset). This evidence indicates that 
AG does not alter significantly the ThT fluorescence spectra from 
fibrillar Aβ alone. The absence in vitro of antiaggregation activity 
of AG was confirmed by TEM micrographs (Figure 5B). TEM 
images indicate that the protein after 24 h of aggregation either 
alone or aggregated in the presence of 3X-AG exists as globular 
micelle-like and prefibrillar assemblies, whereas after 72 h of 
aggregation, the samples are populated mostly of mature fibrils in 
both conditions. Moreover, AG is unable to dissolve preformed 
Aβ fibrils even at 6X-AG concentration after 24 h of treatment, as 
indicated in Figure 5B. The toxicity of the same protein samples 
was assessed on N2a cells by using the MTT reduction assay. The 
amyloid assemblies obtained in the presence of AG or AG NPs 
and the Aβ fibrils obtained with 1X-, 3X-, and preformed fibrils 
treated with 6XAG induced in N2a cells a similar toxicity as well 
as amyloid Aβ (Figures 5C, D). Cell surface staining with GM1 
in N2a cells and immunofluorescent labeling of Aβ showed that 
amyloid species obtained in the absence or in the presence of 
AG or AG NPs were similarly able to bind to the cell membrane 
(Figure 5E). All together, these results indicate that in vitro, the 
AG molecule is not effective to counteract directly amyloid Aβ 
aggregation and the resulting cytotoxicity.
Effect of AG or AG NPs Treatment on 
Viability of N2a Cells
N2a cells were exposed for 4, 24, or 48 h to 1, 2, and 3 µM AG 
(Figure 6A), AG NPs (Figure 6B), or vehicle to evaluate the 
toxicity of the treatment on cell viability by the MTT assay, which 
is based on its reduction by mitochondrial and membrane-
associated dehydrogenases in metabolically active cells. No 
effect of all treatments on cell viability was found at the three 
time periods of AG or AG NP exposure as compared to that of 
control cells. The viability of untreated and vehicle-exposed N2a 
cells was not different, and thus the samples were pooled in the 
control value.
In Vivo Experiments
To exclude potential AG NPs (4 mg/kg, administered i.p. for 
4 weeks) toxicity, the body weight of the animals was recorded 
during the period of treatment. We found that the AG NPs 
were well tolerated, and no evident side effects were revealed, as 
shown by the body weight trend graph of the AG NPs-treated 
mice relative to that of the control represented by the vehicle 
(Figure 7A), and no animals died. To evaluate potential effects 
of AG NPs on cognitive functions and locomotor-exploratory 
abilities at the end of treatment, the animals were tested for 
behavioral performance in the step-down and ORT. In the step-
down inhibitory avoidance test (Figure 7B), two-way ANOVA 
statistical analysis with genotype/treatment and retention time as 
the two variables revealed that there was a significant main effect 
for treatment/genotype [F(2,58) = 121.5, P < 0.001] and retention 
time [F(1,58) = 446.7, P < 0.001] and a significant interaction 
genotype/treatment × retention time [F(2,58) = 100.4, P < 0.001]. 
Latencies observed for untreated Tg mice in the step-down RT 
were significantly reduced when compared to those of wt mice 
(***P < 0.0001). AG NPs treatment of Tg mice significantly 
improved their performance (***P < 0.0001 vs. untreated Tg 
mice) to levels comparable to those displayed by wt mice. In the 
ORT, treated and untreated animals showed no deficiencies in 
exploratory activity, directional movement toward objects, and 
locomotor activity and no cognitive impairments (discrimination 
score) were detected in AG NPs-treated Tg mice (***P < 0.0001 vs. 
untreated Tg mice) (Figure 7C). Next, to evaluate the potential 
therapeutic use of AG NPs in neurodegenerative diseases, such 
as AD, we analyzed the ability of these NPs to penetrate the 
BBB and to migrate in the brain parenchyma in the TgCRND8 
mouse model of Aβ deposition. Thus, the penetration into the 
brain of NAF NPs (green), 200 µl administered acutely i.v., 
was investigated. Three hours after the administration of the 
fluorescent NPs (Figures 8A, B), the formulation was detected 
in the brain parenchyma (arrows) of Tg mice. Interestingly, 
in immunofluorescent analyses with the N3pE antibody that 
recognizes pE3-Aβ plaque, NAF NPs (arrows) were detected both 
in the pE3-Aβ plaque (red) surroundings and inside the pE3-Aβ 
plaque (Figure 8B). This is indicative of the ability of NPs to cross 
the BBB and to penetrate undamaged and damaged brain tissues. 
Moreover, we found, in immunohistochemical study with the 
GFAP antibody (green), that the AG NPs-induced amelioration 
of cognitive functions was associated with a reduced astrocyte 
reaction, revealing fewer reactive astrocytes with enlarged 
cell body in the pE3-Aβ plaque (red) surroundings and brain 
parenchyma in the hippocampus of AG NPs-administered Tg 
mice compared to untreated Tg mice (Figure 9). Overall, these 
data provide strong evidence for the AG NPs efficacy on cognitive 
functions and further support the anti-inflammatory activity of 
AG. AG NPs might represent valuable and safe vectors for brain 
delivery systems, and our present findings indicate that AG can 
be transported across the BBB by NPs and released within the 
brain in a therapeutically relevant concentration.
DISCUSSION
Neurodegenerative diseases, including AD, are the largest 
growing area of neurological research still in search of an effective 
therapy to suppress the main clinical signs and/or to delay the 
occurrence of severe pathologies. AD, the most common form 
of dementia affecting many aged people, is characterized by 
progressive memory loss and neuropathological changes in 
specific regions of the brain (Selkoe, 2013). Recent studies have 
proposed natural products to treat and prevent the progression 
of the disease (Feart et al., 2013; Ng et al., 2015). These are 
principally represented by plant polyphenols (Stefani and 
Rigacci, 2013), which interfere with the amyloid aggregation of 
Aβ peptides (Serrano et al., 2014; Casamenti and Stefani, 2017), 
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FIGURE 5 | Effects of AG on Aβ1-42 aggregation process and resulting cytotoxicity. Aβ aggregation process followed by ThT fluorescence assay (A). The interference 
of AG with the ThT fluorescence assay was evaluated by comparing the emission fluorescence spectra intensity of Aβ1-42 aggregates with respect to when AG was 
added together to the probe or immediately after the probe (A, inset). TEM pictures taken from Aβ1-42 aggregation mixture after 24 and 72 h of incubation in the 
absence or in the presence of 3X-AG (B), first and second lines). TEM pictures taken from preformed Aβ fibrils 72 h aged and successively treated with 6X-AG. 
The scale bars are shown. Cell viability assessed by the MTT reduction assay (C–D). N2a cells treated for 24 h with 2.5 μM Aβ solution obtained at 24 and 72 h 
of aggregation time. Each sample was obtained in the absence or in the presence of 1X- or 3X-AG or AG NPs. For the MTT assay, preformed fibrils treated with 
6X-AG were also tested (C). Error bars indicate the standard deviation of independent experiments carried out in triplicate. Statistical analysis was performed using 
Student’s t-test: *P < 0.05, **P < 0.01 versus untreated cells and *P < 0.05 versus treated cells with Aβ1-42 aggregates grown without AG. The Aβ fibrils grown both 
in the absence and in the presence of AG NPs or NPs bind to the plasma membrane. Z-projection of N2a cell images by Aβ1-42 immunostaining (red) and GM1 
staining (green). The scale bars are shown (E).
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FIGURE 6 | MTT assay in N2a cells exposed to AG (A) or AG NPs (B). N2a cells were seeded into 96 well plates and exposed for 4, 24, or 48 h to 1.0, 2.0, or 
3.0 µM of AG or AG NPs. Viability is expressed as a percentage with respect to that of control untreated cells. Data are reported as mean ± SEM.
FIGURE 7 | (A) Body weight: AG NPs treatment did not affect body weight of Tg and wt mice; (B) step-down inhibitory avoidance test, the training test (black 
bars) showed no significant differences between groups. The 24-h retention test (red bars) showed increased latencies in controls and AG NP-treated Tg mice, as 
compared to their respective training latencies and to the retention latencies of untreated Tg mice (***P < 0.0001). In untreated Tg mice, retention latencies were 
not significantly different from training latencies. (C) ORT test: in the T2 trial, the discrimination index of untreated Tg mice significantly differs from the discrimination 
index of all other groups (***P < 0.0001). The dotted line indicates the chance level performance. Number of animals: n = 6/group.
FIGURE 8 | Immunohistochemical analysis of pE3-Aβ in the cortex of Tg mice. (A) Untreated; (B) treated with NAF NPs. Note the presence of NAF NPs (arrows) in 
the pE3-Aβ plaque surroundings and inside the pE3-Aβ plaque. Scale bar = 20 μm applies to both images.
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whose mechanism is mainly redirecting fibrillar aggregation 
toward the formation of amorphous harmless aggregates without 
the appearance of toxic oligomeric entities (Ladiwala et al., 2011). 
Docking simulations are consistent with the hypothesis of the 
π-π stacking between aromatic phenyl rings of polyphenols and 
aromatic residues of the proteins (Gazit, 2002; Porat et al., 2006). 
Recent studies demonstrated that curcumin intercalates in a 
planar-lengthwise fashion parallel to the fibril axis and disrupts 
interstrand beta sheet chain interactions, precluding ordered fibril 
assembly (Rao et al., 2015). Other studies suggested the presence 
of o-quinone-mediated covalent adduct formation from certain 
flavonoid or catechol-containing compounds with amyloid 
proteins (Velander et al., 2017). Additional covalent mechanisms 
have also been reported between nucleophilic amines and 
thiols of amyloidogenic proteins and electrophilic reactive 
groups on inhibitors such as aldehydes (Li et al., 2009; George 
et al., 2013). Overall, the presence of aromatic/hydrophobic 
moieties and hydrogen-bonding elements along flat extended 
structures commonly observed on aggregation inhibitors appears 
to be determinant shared structural features for inhibition activity.
AG, a bicyclic labdane diterpene from the Chinese 
medicinal plant Andrographis paniculata, has been recognized 
for neuroprotective effects against inflammation-mediated 
neurodegeneration (Wang et al., 2004; Suebsasana et al., 2009), 
oxidative stress in the brain (Das et al., 2009), and cerebral ischemia 
(Chan et al., 2010), but it suffers from low BBB permeation, as 
recently reported (Guccione et al., 2017). Furthermore, Serrano et 
al. (2014) reported that, in young AβPPswe/PS-1 mouse model of 
AD, AG affects amyloid plaque maturation in hippocampi and 
cortices, whereas in old animals, AG was not able to decrease 
the amyloid deposits and Aβ oligomer levels. Moreover, Serrano 
and coworkers showed that AG induces a reduction of tau 
phosphorylation around the Aβ oligomeric species and recovers 
spatial memory functions likely by inhibition of GSK-3 activity. 
In addition, it is reported in the literature that AG reduces several 
neuropathological markers of AD in Octodon degus, the only 
wt South American rodent to develop Alzheimer’s-like pathology 
in older age (Rivera et al., 2016).
To the best of our knowledge, further studies are needed to 
elucidate the biochemical and pharmacological mechanisms that 
underlie the observed AG activities, understanding if the molecule 
is able to prevent or modulate directly the amyloid aggregation 
process. Indeed, this molecule could recover the cognitive 
performances and reduce the neuropathological hallmarks of AD 
by attenuating the toxicity of misfolded Aβ, by converting the toxic 
assemblies into harmless species, or affect the secondary cellular 
signaling pathways triggered by the accumulation of misfolded 
species, for instance, inflammation and oxidative stress.
In the present study, AG NPs suitable for in vivo systemic 
administration were developed, and NAF NPs were evaluated 
for their crossing properties of the BBB and brain distribution 
in TgCRND8 mice. AG NPs were suitable for parenteral 
administration, in terms of shape, size, surface charge, and AG 
loading capacity. The settled method of synthesis through heat was 
environment friendly, simple, highly reproducible, appropriate in 
terms of yield, and easy to scale up. NPs were also very stable in 
terms of physical and chemical properties. Storage for 30 days of AG 
NPs suspension did not affect any physical or chemical parameters.
Release studies were also performed to investigate AG diffusion 
performance in the developed NPs and its release in the physiological 
medium. Results indicated no burst effect, in agreement with the 
absence of superficial adsorbed AG. By contrast, NPs were able 
to release AG for a prolonged period. The quantitative analysis of 
released AG was investigated using several mathematical equation 
models, including first-order and zero-order mathematical models, 
Korsmeyer-Peppas, Higuchi, Hixson Crowell, to understand the 
release pattern of entrapped compound from developed NPs. The 
regression analysis gave the best fit with the Higuchi’s equation. In 
particular, the Higuchi model is based on different hypotheses that 
i) initial drug concentration in the matrix is much higher than drug 
solubility, ii) drug diffusion takes place only in one dimension (edge 
effect should be avoided), iii) drug particles are much smaller than 
thickness of system, iv) swelling of matrix and dissolution are less 
or negligible, v) drug diffusivity is constant, and vi) perfect sink 
conditions are always attained in the release environment (Parmar 
and Sharma, 2018).
FIGURE 9 | Immunohistochemical analysis of GFAP positive astrocytes in the hippocampus of Tg mice. Left panel: untreated Tg mice; right panel): treated (AG 
NPs). GFAP staining (green) revealed less reactive astrocytes, characterized by enlarged cell body, in the pE3-Aβ plaque (red) surroundings of treated (AG NPs) mice 
compared to untreated Tg mice. DAPI is in blue. Scale bar = 20 μm applies to both images.
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In vitro studies were carried out to test the viability of 
N2a cells after treatment with the NPs to assess the safety of 
developed formulations. Both AG and AG NPs did not alter the 
viability of N2a murine neuroblastoma cells when compared 
with the untreated control cells.
In vivo studies demonstrated that AG NPs administered to 
TgCRND8 mice were well tolerated, mice had a stable body 
weight, and no evident side effects were revealed. These data were 
also in agreement with our previous studies with unloaded human 
serum albumin NPs, which did not induce  an  inflammatory 
response after intracerebral injection, and they are biocompatible 
and biodegradable (Bergonzi et al., 2016).
The study demonstrated that impaired cognitive functions of 
TgCRND8 mice in the step-down inhibitory avoidance test and ORT 
were significantly restored 4 weeks after systemic administration of 
AG NPs. Because NAF NPs, systemically administered to TgCRND8 
mice, penetrated into the brain and NPs were detected in undamaged 
and damaged brain parenchyma within the amyloid plaques and 
their surroundings, it might be hypothesized that this functional 
recovery might be related to protective effects of AG NPs on synaptic 
plasticity and synaptic proteins, as suggested by Serrano et al. (2014). 
Furthermore, the immunohistochemical analysis of GFAP-positive 
astrocytes in the hippocampus of Tg mice evidenced the anti-
inflammatory activity of AG when AG NPs were i.p. administered.
In addition, AG ability to prevent or modulate the amyloid 
aggregation process was evaluated. For this aim, the kinetics of 
fibril formation were monitored by following the increase of 
ThT fluorescence emission intensity at 485 nm during the Aβ1-42 
fibrillation process in the absence or in the presence of different 
concentrations of AG. AG did not alter significantly the ThT 
fluorescence spectra from fibrillar Aβ1-42 alone. Moreover, the 
lack of anti-aggregation activity of AG was confirmed by TEM 
micrographs, evidencing that the proteins after 24 h of aggregation 
either alone or aggregated in the presence of AG exist as globular 
micelle-like and prefibrillar assemblies, whereas after 72 h of 
aggregation, the samples are populated mostly of mature fibrils in 
both conditions. Finally, AG was unable to dissolve the preformed 
Aβ fibrils even at very high concentrations. The toxicity of the 
same protein samples was assessed on N2a cells by using the 
MTT reduction assay. The amyloid assemblies obtained in the 
presence of AG or the Aβ preformed fibrils treated with different 
AG concentrations induced in N2a cells the same toxicity as well 
as amyloid Aβ. Overall, our study showed that, in vitro, the AG 
molecule, free or loaded into NPs, is unable to interfere with Aβ1-42 
aggregation process and inhibit the potential toxicity of amyloid 
aggregates by preventing their binding to the cellular membrane.
CONCLUSION
Overall, these data provided strong evidence for the delivery of 
AG NPs to the brain and their efficacy on cognitive functions. Our 
results indicate that AG does not show any anti-amyloid activity 
in vitro, and its healthy effects could be the logical outcome of its 
anti-inflammatory role and reduced  astrocyte activation. The 
neuroinflammation in addition to Aβ deposition is one of the 
major causes  of neuronal loss and synaptic dysfunction in AD; 
the inflammation can modify the  neuron-astrocyte-microglia 
interaction in CA1 and CA3 (Lana et al., 2017), leading to a decline 
in hippocampal functions and memory impairment. Considering 
AD as a multifactorial disease, involving various genetic 
and  environmental risk factors, with resulting amyloid and tau 
abnormalities, it seems valid to target more than one element in the 
disease pathology to potentiate the therapeutic outcome. Indeed, a 
future goal could be to assess the efficacy and safety of combination 
therapy with the efficient  treatment  properties of AG  added to 
amyloid- or tau-directed treatments by using  NPs as  vehicle, 
following the example of successful  treatment combinations for 
other serious diseases and conditions, such as cancer. In conclusion, 
our present findings indicate that the developed NPs are transported 
across the BBB, thus representing valuable and safe vectors for 
brain delivery  systems, and  that AG can be released within the 
brain in a  therapeutically relevant concentration. In conclusion, 
the formulated NPs represent a  very attractive strategy because 
of the extraordinary versatility, nontoxicity, nonimmunogenicity, 
strong biocompatibility, high biodegradability, astonishing loading 
capacity of AG, and well tolerability without any serious side effects.
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